Indeed, MSLN-based immunotherapies have been proposed for different MSLN-expressing malignancies, such as PDAC itself, ovarian cancer, malignant mesothelioma, and lung adenocarcinoma [35,36]. The gene discussed is MSLN; the disease is ovarian cancer.